At a glance
ClinicalIndex Comparison RecordN/ACompleted· 340 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Dosage of MIRCERA in the Treatment of Renal Anaemia in Patients With Chronic Renal Disease Who do Not Undergo Haemodialysis in Clinical Practice
In Brief
An observational study for Kidney Disease, Chronic. Completed, enrolled 340 participants across 1 site.
Detailed Summary
This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease. Patients are not on dialysis and are naive to, or have received erythropoiesis stimulating agent treatment. Data will be collected for 10 months.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Disease, Chronic
CountriesCzechia
Collaborators--
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2010
First PostedMar 2011
Primary CompletionDec 2013
TodayJul 2026
First PostedMar 18, 2011
Enrollment StartJul 31, 2010
Primary CompletionDec 31, 2013
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 15.3 years ago